Hims & Hers Health, Inc. (HIMS) — ESG & Values Scores

Environment story

HIMS operates primarily as a digital telehealth and pharmacy platform with minimal direct operational carbon footprint typical of technology-enabled healthcare. The company has not disclosed Scope 1, Scope 2, or Scope 3 emissions targets, net-zero commitments, or renewable energy percentages. No environmental controversies, fines, or resource-extraction activities are disclosed. The company's environmental impact is indirect via supply-chain pharmacy operations and data-center reliance on AWS. Absence of disclosed climate commitments, carbon metrics, and net-zero targets results in significant penalty. The company's GLP-1 compounding and distribution operations introduce supply-chain complexity but do not directly implicate environmental hazards beyond standard pharmaceutical logistics. No greenwashing detected (no offset claims or misleading sustainability statements identified). Environmental score reflects absence of material environmental risks but also complete absence of proactive climate governance or disclosure.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

No disclosed initiatives on file for this pillar.

Social story

HIMS has experienced rapid headcount expansion (1,046 employees in Dec 2023 to 2,442 in Dec 2025, 133% growth in 24 months), creating operational and talent-retention strain acknowledged in 10-K risk disclosures. No CEO-to-worker pay ratio, diversity metrics, turnover rates, or union-standing data disclosed in available filings. The 10-K does not reference union organizing, NLRB complaints, strikes, or formal labor disputes within the last 24 months. Supply-chain risk acknowledged for compounded GLP-1 manufacturing and pharmaceutical fulfillment; no human-rights audit or ethical-sourcing certification disclosed for manufacturing suppliers or Partner Pharmacies. The company uses independent-contractor model for Affiliated Medical Group providers, creating classification risk but no documented disputes reported. No diversity or pay-equity commitments identified in filings. Social score reflects high growth strain, absence of disclosed diversity/pay data, and supply-chain labor opaqueness, partially offset by lack of active documented labor disputes.

Criticisms on file

Provider Independent-Contractor Classification Risk
Source: HIMS 10-K Risk Factors: 'Foreign, state, and local laws governing the definition or classification of independent contractors...could require classification of Providers as employees...If the Affiliated Medical Groups are required to classify Providers as employees...it could result in significant additional expenses.'
Absence of Disclosed Diversity or Pay-Equity Metrics
Source: HIMS 10-K filing contains no EEO-1 disclosures, CEO-to-worker ratios, diversity percentages, or pay-equity commitments.

Disclosed initiatives

Rapid Workforce Expansion

Company grew from 1,046 to 2,442 employees (133% increase) between Dec 2023 and Dec 2025, indicating significant hiring and integration challenges.

Acknowledged management strain; risk of quality-of-hire and cultural integration issues.

Governance story

HIMS operates under a dual-class share structure with Class A and implied superior-voting Class B shares, concentrating voting control with CEO and Co-Founder Andrew Dudum. The 10-K explicitly states: 'Our dual class common stock structure has the effect of concentrating voting power with our Chief Executive Officer and Co-Founder, Andrew Dudum, which limits an investor's ability to influence the outcome of important transactions, including a change in control.' This structure triggers a 20-point penalty. Board independence percentage not disclosed in 10-K; cannot verify against 75% threshold. No active lobbying expenditures disclosed targeting environmental deregulation or consumer-protection rollbacks; company is primarily defensive in regulatory posture (responding to telehealth, pharmacy, compounding, and GLP-1 restrictions). Significant regulatory scrutiny documented: FDA Statement (Feb 2026) naming HIMS directly regarding GLP-1 compounding restrictions; HHS referral to DOJ for investigation regarding FDCA and Title 18 violations. These regulatory proceedings do not constitute antitrust or fraud violations but represent active enforcement risk. No SEC consent decrees, privacy fines, or antitrust settlements identified in 10-K. Governance score reflects dual-class penalty, undisclosed board independence, and active regulatory proceedings (GLP-1/compounding investigations), partially offset by absence of major financial or antitrust penalties.

Criticisms on file

Dual-Class Share Structure Concentrating Voting Power
Source: HIMS 10-K Item 1A Risk Factors: 'Our dual class common stock structure has the effect of concentrating voting power with our Chief Executive Officer and Co-Founder, Andrew Dudum, which limits an investor's ability to influence the outcome of important transactions, including a change in control.'
DOJ Investigation Referral for GLP-1 Compounding Violations
Source: HIMS 10-K Risk Factors (Feb 2026): 'In February 2026, the General Counsel of HHS issued a statement on X indicating that HHS had referred the Company to the Department of Justice (the DOJ) for investigation for potential violations of the FDCA and applicable Title 18 provisions.'
FDA Restrictive Guidance on Compounded GLP-1s Targeting HIMS
Source: HIMS 10-K Risk Factors (Feb 2026): 'In February 2026, the FDA issued a statement (the FDA Statement) indicating that the agency intends to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed as similar alternatives to FDA-approved drugs. We were directly named in the FDA Statement.'

Disclosed initiatives

Compliance Infrastructure for Healthcare Operations

Company operates dedicated compliance and legal functions to manage pharmacy licenses, telehealth regulations, compounding compliance, and multi-jurisdictional healthcare requirements across US and international markets (UK, Germany, Ireland, France, Spain, Canada, Australia, Japan).

Reduces regulatory violation risk but does not eliminate emerging GLP-1 compounding enforcement risk.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Hims & Hers Health, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Hims & Hers Health, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)